共 47 条
[1]
Kavanaugh A(2014)Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Ann Rheum Dis 73 1020-6
[2]
Mease PJ(2015)Secukinumab Inhibition of interleukin-17A in patients with psoriatic arthritis N Engl J Med 373 1329-39
[3]
Gomez-Reino JJ(2006)Classification criteria for psoriatic arthritis: development of new criteria from a large international study Arthritis Rheum 54 2665-73
[4]
Adebajo AO(2010)Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment Ann Rheum Dis 69 48-53
[5]
Wollenhaupt J(2016)Radiographic progression of patients with psoriatic arthritis who achieve minimal disease activity in response to golimumab therapy: results through 5 years of a randomized, placebo-controlled study Arthritis Care Res (Hoboken) 68 267-74
[6]
Gladman DD(2008)Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis Arthritis Rheum 58 3063-70
[7]
Mease PJ(2011)“Treat-To-Target” aus der Sicht der niedergelassenen Rheumatologie Z Rheumatol 70 664-9
[8]
McInnes IB(2013)A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control Int J Rheum Dis 16 532-8
[9]
Kirkham B(2016)When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS) RMD Open 2 e000221-undefined
[10]
Kavanaugh A(undefined)undefined undefined undefined undefined-undefined